Our pipeline in the field of epilepsy currently includes two product candidates: Epidiolex® (cannabidiol or CBD) and GWP42006 (cannabidivarin or CBDV). Currently, there are no planned trials for CBDV in the U.S.
Epidiolex (CBD) is a liquid formulation of pure plant-derived cannabidiol and is being investigated as a treatment for various orphan childhood-onset epilepsy syndromes. We have been conducting pre-clinical research of CBD in epilepsy since 2007. Based upon research using a variety of in vitro and in vivo models, we have progressed into clinical trials.
Our strategy for the development of Epidiolex (CBD) within the field of childhood-onset epilepsy is to initially concentrate formal development efforts on four orphan indications: DS, LGS, TSC, and IS, each of which are severe infantile-onset, drug-resistant epilepsy syndromes. We expect to investigate additional orphan seizure disorders.
Epidiolex (CBD) is an investigational drug not approved for any indication.